TheraVet Announces the Signing of a Research Contract With Degroof Petercam
09 Novembre 2021 - 7:30AM
Business Wire
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in companion
animals, announces today, the signing of a research contract
with Degroof Petercam.
Banque Degroof-Petercam will initiate coverage of the Company
through its sponsored research program, and support the Company in
investors networking with roadshows and conferences through its
corporate access services.
About TheraVet SA TheraVet is a veterinary biotechnology
company specialising in osteoarticular treatments for animals. The
Company develops targeted, safe and effective treatments to improve
the quality of life of pets suffering from osteoarticular diseases.
For pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris and Brussels, its head office is
in Gosselies, Belgium, and it has a subsidiary in the US.
For more information, visit www.thera.vet.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211108006094/en/
TheraVet Sabrina Ena Chief Operating Officer
sabrina.ena@thera.vet
Julie Winand Chief Corporate Officer julie.winand@thera.vet
NewCap Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud theravet@newcap.eu +33 (0)1 44 71
94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
+33 (0)1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024